Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced NSCLC with FGFR Alterations
NCT05253807Phase 2Completed
- Sponsor
- Incyte
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 5
01
Overview
Phase 2, open-label trial of pemigatinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Incyte. Primary endpoint: Objective Response Rate up to 267 days. Started Apr 2022; status: completed.
02
Drugs
pemigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05253807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253807.